CELATOR RECEIVES FDA APPROVAL OF IND, EU PATENT FOR LEUKEMIA TREATMENT

Celator Pharmaceuticals announced that the FDA recently approved an investigational new drug (IND) application for CPX-351, the second combination chemotherapy in development based on Celator's CombiPlex technology. CPX-351 is a synergistic, fixed-ratio combination of cytarabine and daunorubicin in development as a potential treatment for acute myeloid leukemia. The company plans to initiate a Phase I study for CPX-351 in late 2006.

The company also announced that it has received confirmation that the Examining Division of the European Patent Office intends to grant a European patent covering the company's proprietary CombiPlex technology.